Who are Tavaborole 5% Topical Solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Terbinafine Tablets, Lotrimin Ultra®, NAFT600 (pediatric), NAFT500 (pediatric), Jublia®, AN2690 Topical Solution, 5%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tavaborole-5-topical-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Tavaborole 5% Topical Solution — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tavaborole 5% Topical Solution (Tavaborole 5% Topical Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Benzoxaborole antifungal. Area: Dermatology/Infectious Disease.

marketed Benzoxaborole antifungal Squalene epoxidase Dermatology/Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Tavaborole 5% Topical Solution (Tavaborole 5% Topical Solution) — Pfizer. Tavaborole inhibits fungal squalene epoxidase, disrupting ergosterol synthesis and causing fungal cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tavaborole 5% Topical Solution TARGET	Tavaborole 5% Topical Solution	Pfizer	marketed	Benzoxaborole antifungal	Squalene epoxidase
Terbinafine Tablets	Terbinafine Tablets	Oregon Health and Science University	marketed	Allylamine antifungal	Squalene epoxidase
Lotrimin Ultra®	Lotrimin Ultra®	Sun Pharmaceutical Industries, Inc.	marketed	Allylamine antifungal	Squalene epoxidase
NAFT600 (pediatric)	NAFT600 (pediatric)	Merz North America, Inc.	marketed	Topical antifungal (allylamine)	Squalene epoxidase (fungal)
NAFT500 (pediatric)	NAFT500 (pediatric)	Merz North America, Inc.	marketed	Allylamine antifungal	Squalene epoxidase
Jublia®	Jublia®	Dong-A ST Co., Ltd.	marketed	Azole antifungal	Squalene epoxidase (fungal)
AN2690 Topical Solution, 5%	AN2690 Topical Solution, 5%	Pfizer	phase 3	Topical antifungal (squalene epoxidase inhibitor)	Squalene epoxidase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Benzoxaborole antifungal class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tavaborole 5% Topical Solution — Competitive Intelligence Brief. https://druglandscape.com/ci/tavaborole-5-topical-solution. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing